FDA safety alert for compounded glutamine, arginine, and carnitine product for injection by United Pharmacy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: FDA received an adverse event report stating that two patients developed what is described in the report as tissue erosion at the injection site following the administration of an injectable glutamine, arginine, and carnitine (GAC) product that was compounded by United Pharmacy, LLC, located in West Palm Beach, Florida. According to the report, a sample of the product was sent for testing and the pH was determined to be above 11. FDA conducted a for-cause inspection of United Pharmacy and collected samples from two batches of GAC injectable product. Analysis performed on the samples determined the pH to be 10.9, which is alkaline, and no glutamine was detected. Parenteral drugs, including compounded injectable drugs, with a high pH may lead to skin damage or other unintended health consequences.

Compounded drugs have not been evaluated by FDA for safety, effectiveness, and quality. There is no FDA-approved injectable GAC product.

BACKGROUND: United Pharmacy recalled lots GAC-12 and GAC-13 on September 27, 2017.

RECOMMENDATION: Compounding pharmacies should be aware of saf...

Recommended for you

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Increased risk of heart-related death with febuxostat (Uloric)

  • MedWatch Drug Updates
  • 1 comment

Recall of Nexterone (amiodarone HCl) 150 mg/100 mL premixed injection by Baxter- Presence of particulate matter

  • MedWatch Drug Updates
  • 1 comment

FDA warns against use of injectable silicone for body contouring and enhancement

  • MedWatch Drug Updates
  • 1 comment

FDA safety alert for compounded glutamine, arginine, and carnitine product for injection by United Pharmacy

  • MedWatch Drug Updates
  • 1 comment

Recall of DBA pain relief naturally products by Ridge Properties: Violation of GMP

  • MedWatch Drug Updates
  • 1 comment

Voluntary field action for Infant/Child Reduced Energy Defibrillation Electrodes by Cardinal Health

  • MedWatch Drug Updates
  • 1 comment

Recall of Midazolam injection, USP, 2 mg/2 mL by Fresenius Kabi: contains different drug

  • MedWatch Drug Updates
  • 1 comment

FDA update: Risk of major adverse cardiac events with the use of Absorb GT1 Bioresorbable Vascular Scaffold

  • MedWatch Drug Updates
  • 1 comment

FDA update: Type III endoleaks associated with the use of endovascular graft systems

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Bridge Occlusion Balloon Catheter Model 590-001 by Spectranetics: Blocked guidewire lumen

  • MedWatch Drug Updates
  • 1 comment

FDA update: High risk of mortality and neurological adverse events when using SynCardia's TAH-t C2 Driver System

  • FDA Drug Updates
  • 1 comment

FDA approved Aliqopa (copanlisib) for the treatment of relapsed follicular lymphoma

  • FDA Drug Updates
  • 1 comment

FDA approved Mvasi (bevacizumab-awwb) for the treatment of cancer

  • MedWatch Drug Updates
  • 1 comment

Voluntary market withdrawal of Octagam 10% immune globulin IV (human) liquid preparation by Octapharma

  • MedWatch Drug Updates
  • 1 comment

Recall of injectable products by SCA Pharmaceuticals: Products may contain microbial contamination

  • MedWatch Drug Updates
  • no comment

FDA recommends separate dosing for Kayexalate (sodium polystyrene sulfonate) from all other oral drugs

  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Intra-Aortic Balloon Pump by Datascope/MAQUET- False blood detection alarm and ingress of fluid into the pump

  • MedWatch Drug Updates
  • 1 comment

FDA statement on risks of unapproved use of Keytruda (pembrolizumab) for treatment of multiple myeloma

  • MedWatch Drug Updates
  • 1 comment

Recall of Piyanping Anti-Itch Lotion by Lucky Mart Inc.: Contain wrong active pharmaceutical ingredient

  • FDA Drug Updates
  • 1 comment

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

  • FDA Drug Updates
  • 1 comment

New targeted treatment approved for relapsed or refractory acute myeloid leukemia

  • MedWatch Drug Updates
  • 1 comment

Recall of Intralipid 20 % IV Fat Emulsion by Baxter: One lot of product exposed to subfreezing temperature

  • MedWatch Drug Updates
  • 1 comment

Class I recall of Penumbra 3D Revascularization device by Penumbra: delivery wire may break or separate during use

  • MedWatch Drug Updates
  • 1 comment

Case of HORV reported after intraocular Inj of a compounded triamcinolone, moxifloxacin, vancomycin

  • FDA Drug Updates
  • 1 comment

FDA approved Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for Hepatitis C

  • MedWatch Drug Updates
  • 1 comment

FDA alert- Not to use infant sleep positioners as it can cause suffocation

  • FDA Drug Updates
  • 1 comment

FDA approved Nerlynx (neratinib) for breast cancer

  • FDA Drug Updates
  • no comment

FDA approved Endari (L-glutamine) for sickle cell disease

  • MedWatch Drug Updates
  • 1 comment

Recall of Novopen Echo Insulin Delivery Device by Novo Nordisk: Chemical exposure may damage cartridge holder

  • MedWatch Drug Updates
  • 1 comment

Recall of Atar Extension Cables by Oscor- cable malfunction interrupting the pacing system